ABSTRACT Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder where the immune system targets and destroys insulin‐producing β‐cells in the pancreas. It generally emerges during childhood or adolescence, but individuals of any age can be affected. In contrast to Type 2 diabetes mellitus (T2DM) which is often associated with lifestyle factors, T1DM cannot be prevented and necessitates lifelong management. Currently, there is no definitive cure for T1DM, and patients rely on continuous insulin injections for their entire lives. Ongoing developments in insulin treatment, such as insulin pumps, continuous glucose monitoring, and hybrid closed‐loop systems, offer promising alternatives. Despite advancements in intensive glycemic control that have reduced the occurrence of microvascular and macrovascular complications, a significant number of T1DM patients still these issues. Extensive research efforts are crucial to achieve early detection, prevent the loss of β‐cells, and devise improved treatment strategies to enhance the quality of life and prognosis for those affected. This review explores the most noteworthy and recent advancements in the field of T1DM.
Ebrahimpour et al. (2025) studied this question.